Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: Are we changing life expectancy?
dc.contributor.author | Spector, Matthew E. | en_US |
dc.contributor.author | Chinn, Steven B. | en_US |
dc.contributor.author | Rosko, Andrew J. | en_US |
dc.contributor.author | Worden, Francis P. | en_US |
dc.contributor.author | Ward, P. Daniel | en_US |
dc.contributor.author | Divi, Vasu | en_US |
dc.contributor.author | McLean, Scott A. | en_US |
dc.contributor.author | Moyer, Jeffrey S. | en_US |
dc.contributor.author | Prince, Mark E. P. | en_US |
dc.contributor.author | Wolf, Gregory T. | en_US |
dc.contributor.author | Chepeha, Douglas B. | en_US |
dc.contributor.author | Bradford, Carol R. | en_US |
dc.date.accessioned | 2012-07-12T17:26:06Z | |
dc.date.available | 2013-09-03T15:38:28Z | en_US |
dc.date.issued | 2012-07 | en_US |
dc.identifier.citation | Spector, Matthew E.; Chinn, Steven B.; Rosko, Andrew J.; Worden, Francis P.; Ward, P. Daniel; Divi, Vasu; McLean, Scott A.; Moyer, Jeffrey S.; Prince, Mark E. P.; Wolf, Gregory T.; Chepeha, Douglas B.; Bradford, Carol R. (2012). "Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: Are we changing life expectancy? ." The Laryngoscope 122(7): 1507-1511. <http://hdl.handle.net/2027.42/92128> | en_US |
dc.identifier.issn | 0023-852X | en_US |
dc.identifier.issn | 1531-4995 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/92128 | |
dc.description.abstract | Objectives/Hypothesis: To determine if the various imaging modalities for distant metastasis (DM) diagnosis alters life expectancy in head and neck squamous cell carcinoma (HNSCC). Study Design: Retrospective. Methods: One hundred seventy patients (mean age, 59.1 years; male:female, 135:35) with HNSCC who developed DM were reviewed. The main outcome measures were the method of DM diagnosis and time from DM diagnosis to death while controlling for clinical parameters (age, gender, tobacco status, primary tumor site, initial TNM classification, number and site of DM, administration of palliative chemotherapy). Results: Tumor subsites were: 40 oral cavity, 75 oropharynx, 36 larynx, 10 hypopharynx, one nasopharynx, and eight unknown primary. Of the patients, 16.5% (28/170) had distant metastasis at presentation; the remaining 142 patients were diagnosed with DM at a median of 324 days from diagnosis. Although patients diagnosed with DM by positron‐emission tomography (PET) scan were more likely to have multiple DM sites ( P = .0001), there were no differences in life expectancy in patients who were diagnosed with or without PET scan (median, 185 vs. 165 days, P = .833). There were no differences in life expectancy based on age, gender, site of primary tumor, or number/site of DM. The use of palliative chemotherapy resulted in a significantly longer life expectancy (median, 285 vs. 70 days; P = .001). Conclusions: Although a PET scan is more likely to diagnose multiple DM sites, there was no difference in life expectancy based on imaging modality. Patients who are symptomatic from their distant metastasis have a worse life expectancy, and palliative chemotherapy was able to increase life expectancy, even in patients who were symptomatic from the distant metastasis. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Distant Metastasis | en_US |
dc.subject.other | Survival | en_US |
dc.subject.other | Head and Neck Cancer | en_US |
dc.subject.other | Positron Emission Tomography Scan | en_US |
dc.subject.other | Level of Evidence: 2b | en_US |
dc.title | Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: Are we changing life expectancy? | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Otolaryngology–Head and Neck Surgery, and Department of Internal Medicine, Medical Oncology, University of Michigan Health System, Ann Arbor, Michigan, U.S.A. | en_US |
dc.contributor.affiliationother | 1904 Taubman Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109 | en_US |
dc.identifier.pmid | 22460441 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/92128/1/23264_ftp.pdf | |
dc.identifier.doi | 10.1002/lary.23264 | en_US |
dc.identifier.source | The Laryngoscope | en_US |
dc.identifier.citedreference | Alvi A., Johnson JT. Development of distant metastasis after treatment of advanced‐stage head and neck cancer. Head Neck 1997; 19: 500 – 505. | en_US |
dc.identifier.citedreference | Calhoun KH, Fulmer P, Weiss R, Hokanson JA. Distant metastases from head and neck squamous cell carcinomas. Laryngoscope 1994; 104: 1199 – 1205. | en_US |
dc.identifier.citedreference | Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001; 23: 1056 – 1060. | en_US |
dc.identifier.citedreference | Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F‐FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25: 1255 – 1260. | en_US |
dc.identifier.citedreference | Stokkel MP, ten Broek FW, Hordijk GJ, Koole R, van Rijk PP. Preoperative evaluation of patients with primary head and neck cancer using dualhead 18fluorodeoxyglucose positron emission tomography. Ann Surg 2000; 231: 229 – 234. | en_US |
dc.identifier.citedreference | Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20: 4199 – 4208. | en_US |
dc.identifier.citedreference | Jacobs C, Lyman G, Velez‐Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257 – 263. | en_US |
dc.identifier.citedreference | Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous‐cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245 – 1251. | en_US |
dc.identifier.citedreference | Argiris A, Li Y, Forastiere A. Prognostic factors and long‐term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101: 2222 – 2229. | en_US |
dc.identifier.citedreference | Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283 – 289. | en_US |
dc.identifier.citedreference | Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ. F‐18‐fluoro‐deoxy‐glucose positron‐emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/ pharyngeal cancer. Head Neck 2001; 23: 933 – 941. | en_US |
dc.identifier.citedreference | Lapela M, Eigtved A, Jyrkkio S, et al. Experience in qualitative and quantitative FDG PET in follow‐up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000; 36: 858 – 867. | en_US |
dc.identifier.citedreference | Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F‐18]fluorodeoxyglucose positron emission tomography. Head Neck 1997; 19: 666 – 674. | en_US |
dc.identifier.citedreference | Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002; 24: 127 – 135. | en_US |
dc.identifier.citedreference | Hannah A, Scott AM, Tochon‐Danguy H, et al. Evaluation of 18 F‐fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002; 236: 208 – 217. | en_US |
dc.identifier.citedreference | Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18: 651 – 658. | en_US |
dc.identifier.citedreference | Recondo G, Armand JP, Tellez‐Bernal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin‐based chemotherapy. Laryngoscope 1991; 101: 494 – 501. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.